All News

eye%20exa.jpg (keep)

ACR and Three Societies Agree on HCQ Eye Safety

MedPage Today

Four major medical societies issued a joint statement of principles on safe use of hydroxychloroquine from the perspective of ocular toxicity.

Read Article
gout podagra inflammed

MIRROR Study: Pegloticase With Methotrexate in Uncontrolled Gout

Jack Cush, MD

Botson et al has reported that the combination of methotrexate (MTX) and IV pegloticase is safe and effective in patients with uncontrolled gout.

This exploratory, open-label clinical trial screened 17 patients and treated 14 patients (all men, 49.3 ± 8.7 years) with IV pegloticase with MTX (15 mg/week) and folic acid (1 mg/day) 4 weeks prior to and throughout pegloticase treatment.

Read Article
rwcsmtg.jpeg

RWCS Highlights - Day 3

Rachel Tate, DO

Day 3 report from the 2021 RWCS meeting in Maui (and virtually) includes pearls from the PsA 2020 Year in Review; fact vs. fiction on evidence based medicine: diet and rheumatic diseases; hot topics in allergy/immunology; and pediatric rheumatology highlights.

Read Article
COVID vaccine vials

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Jack Cush, MD

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.

Read Article
RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Fails to Prevent COVID-19

Jack Cush, MD

There is a preponderance and mounting evidence that hydroxychloroquine is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons.

Read Article
30 #RA pts treated w/ tofacitinib x 12 mos w/ signif improvement in DAS28, CRP, & HAQ and attenuation of further bone loss, as measured by significantly increased osteocalcin, OPG, and vitamin D3, with decreased CTX levels correlating w/ DXA results https://t.co/RSXL38cJvs

Links:

Dr. John Cush RheumNow ( View Tweet)

EXCEED study in #PsA shows lower responses in women (vs men) treated with either secukinumab or adalimumab. Question is, why? @RWCSmtg @JointMD https://t.co/LFBQi1jtiu
Dr. John Cush RheumNow ( View Tweet)
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush RheumNow ( View Tweet)
Congrats to ACR Task Force who published guidelines on RMD drug use w/ COVID vaccines. My views on their recs: 1. I agree, no change most DMARD, biologics 2. I disagree; I would NOT hold Orencia, I would NOT hold JAKi 3. I disagree: I would not hold MTX https://t.co/uSPfvJB8EC https://t.co/SznUJosmpo

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Tofacitinib Safety Concerns https://t.co/rqNoiLB3xr https://t.co/rmlw2T0Cif

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Sawtooth Steroid Taper How I Taper Steroids - the Sawtooth way https://t.co/PNMV3Pjbxc

Links:

Dr. John Cush RheumNow ( View Tweet)

Abrupt Cessation of Long-Term Opioid Prescribing Common Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed. https://t.co/bCnaJHECd0 https://t.co/PfM9BCNPyC

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab, a bispecific mAb inhibits IL-7F & IL-17A, was testedin PhIII trial in Active psoriasis and show to be more effective than ustekinumab and placebo. 567 PSO pts - at wk 16, PASI90 was BMKZ 85% vs Ustekinumab 50%, vs 5% in placeob (p<0·0001) https://t.co/Z4ZQEHO4rX

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Tofacitinib Safety Concerns - covering vagal nerve stimulation, IL-23 in PsA, Diet & RA, NSAIDs & COVID, Plaquenil side effects and more. Watch it here>> https://t.co/7RDZ0avZLC ListeniTunes>>https://t.co/FHJv01AAbC or SoundCloud>>https://t.co/yJWJNa6CRL

Links:

Dr. John Cush RheumNow ( View Tweet)

Abrupt Cessation of Long-Term Opioid Prescribing Common Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed. https://t.co/bCnaJHECd0 https://t.co/ermkbK6LMN

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Tofacitinib Safety Concerns Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow. https://t.co/7RDZ0avZLC https://t.co/iUJFuf8PNj

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB

Links:

Dr. John Cush RheumNow ( View Tweet)
Adverse Events with Anti-malarials during the COVID Pandemic Despite very preliminary mixed results, the endorsement of chloroquine and hydroxychloroquine use to treat COVID-19 led substantial use (and drug shortages) for these drugs. https://t.co/UQYo3a8ZKI

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×